Labiotech.eu

News and Trends 16 Mar 2017

Researchers Develop New Virus to Selectively Attack Tumor Cells

Researchers from Barcelona have developed a new genetically engineered oncolytic virus, which can selectively infect and kill tumor cells. Eneko Villanueva and colleagues from the IDIBAPS Biomedical Research Institute and the Institute for Research in Biomedicine (IRB Barcelona) have engineered a virus that infects tumor cells without affecting healthy tissues. Their new cancer therapy approach is based […]

March 16, 2017 - 3 minutesmins - By Melanie De Almeida

News and Trends 16 Mar 2017

UK Immunotherapy Biotech raises Massive Funding in Series C

The UK biotech Cell Medica picked up a massive €69M (£60M) in its recent Series C funding round to advance its cancer immunotherapy programs. Cell Medica is a clinical stage company developing cell-based therapies to treat cancer. With the aim of advancing the clinical development of its immunotherapies, the company was able to raise an impressive […]

March 16, 2017 - 3 minutesmins - By Melanie De Almeida

News and Trends 16 Mar 2017

What’s Berlin’s Secret to Success in Biotech & Digital Health?

Berlin is a creative crossroads not just for arts but also life science. A variety of players in academia, industry, and startups make the ecosystem blossom. To those who know Berlin as a creative hub, it might come as a surprise that life science is one of the city’s industrial pillars. The German capital region […]

March 16, 2017 - 8 minutesmins - By External Contributor

News and Trends 15 Mar 2017

France Closes in on an HIV Cure by Detecting Cells with Dormant Viruses

French researchers have found a protein only expressed in HIV-infected reservoir cells, paving the way for an HIV cure that completely eliminates the virus. Researchers from the Institut de Génétique Humaine (IGH) at Montpellier University, France, have discovered a protein, CD32a, that is only present on the surface of CD4 T cells infected with dormant HIV. This […]

March 15, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Allergan Editas Medicine CRISPR eye disease

News and Trends 15 Mar 2017

Allergan makes a deal with Editas to License CRISPR Programs for Eye Disease

Allergan has signed a deal with Editas Medicine to access its CRISPR technology and license up to five of its programs in ocular disease. The Irish Allergan has a certain tendency to go on shopping sprees. Its latest deal is a research and development alliance with the American Editas Medicine, which is on the side of […]

March 15, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Best in Biotech 15 Mar 2017

What are the Best Countries to Recruit Biotech Talents in 2017?

Before the “who to recruit” phase, an important question is “where?” We ran through the top countries in which to look for talent in biotech and had a look at what you can expect from each cluster. For each one of them, we also referenced some data on the biotech, life science and research ecosystems to […]

March 15, 2017 - 10 minutesmins - By External Contributor

News and Trends 14 Mar 2017

Huge Successful €103M IPO for the Next European Leader in Bioplastics

Avantium has gone public and raised €103M on Euronext Amsterdam and Euronext Bruxelles with Sofinnova Partner as the main shareholder. Avantium, a spin-off from Shell, is developing renewable bioplastics made 100% from plant-based materials with the support of big partners such as Coca-Cola or Danone, for which the Dutch biotech is developing sustainable PlantBottles and yogurt cups, […]

March 14, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

roche morphosys antibody alzheimers gantenerumab 1

News and Trends 14 Mar 2017

Can Roche & MorphoSys beat the odds in new Alzheimer’s Phase III Trials?

After recent late-stage disappointments from Eli Lilly and Merck, Roche and Morphosys are stepping up with two new Phase III trials in Alzheimer’s. Roche just announced plans to start two new Phase III studies in Alzheimer’s with its antibody candidate gantenerumab, initially developed by the German biotech giant MorphoSys. The trials are expected to begin later this year, but Roche […]

March 14, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 14 Mar 2017

The First 3D Structure of Active DNA could advance Stem Cell Therapies

Scientists from the University of Cambridge have determined the first 3D structures of mammalian genomes from individual cells. For the first time, researchers from the University of Cambridge were able to determine the 3D structure of an active mouse genome in embryonic stem cells. Tim Stevens and his colleagues used a combination of imaging and […]

March 14, 2017 - 3 minutesmins - By Melanie De Almeida

Spain biotech ecosystem Joan Perello Sanifit Joel Jean Mairet Ysios Luis Mora PharmaMar

Interview 14 Mar 2017

Spain’s Biotech Ecosystem is Starting to Rise! Meet the Revolution’s Leaders

I interviewed three of the leaders of Spain’s biotech ecosystem: they all agree that the country is at an inflection point for growth and international recognition. This all started when I realized there’s usually far less biotech news coming our way from my home country, Spain, than from the UK, France or Germany. I decided to […]

March 14, 2017 - 8 minutesmins - By Clara Rodríguez Fernández

Interview 13 Mar 2017

Infographic: The Microbiome Market & Research by the Numbers

A new infographic from Intellisness describes global therapeutic efforts in the microbiome through target indications, investment and patents. Image from freedomnaruk / shutterstock.com

March 13, 2017 - 1 minutemin - By Evelyn Warner

Tigenix AlloCSC 01 stem cell therapy AMI

News and Trends 13 Mar 2017

New Cardiac Stem Cell Therapy passes Phase I/II Trials

TiGenix announces positive one-year results for its phase I/II trial of donor-derived cardiac stem cell therapy in acute myocardial infarction (AMI). The Belgian biotech TiGenix is developing allogeneic stem cell therapies. Now the company has announced that its cardiac stem cell therapy AlloCSC-01 reached its primary endpoints in a phase I/II trial. In 2015, the company acquired Coretherapix in a €292M deal for its allogeneic cardiac stem […]

March 13, 2017 - 3 minutesmins - By Melanie De Almeida

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Researchers Develop New Virus to Selectively Attack Tumor Cells

UK Immunotherapy Biotech raises Massive Funding in Series C

What’s Berlin’s Secret to Success in Biotech & Digital Health?

France Closes in on an HIV Cure by Detecting Cells with Dormant Viruses

Allergan makes a deal with Editas to License CRISPR Programs for Eye Disease

What are the Best Countries to Recruit Biotech Talents in 2017?

Huge Successful €103M IPO for the Next European Leader in Bioplastics

Can Roche & MorphoSys beat the odds in new Alzheimer’s Phase III Trials?

The First 3D Structure of Active DNA could advance Stem Cell Therapies

Spain’s Biotech Ecosystem is Starting to Rise! Meet the Revolution’s Leaders

Infographic: The Microbiome Market & Research by the Numbers

New Cardiac Stem Cell Therapy passes Phase I/II Trials

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!